Abortion in the United States Dashboard
The Abortion in the U.S. Dashboard is an ongoing research project tracking state abortion policies and litigation following the overturning of Roe v. Wade.
The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
The Abortion in the United States Dashboard is an ongoing research project tracking state abortion policies and litigation following the overturning of Roe v. Wade. It features a continuously-updated map tracking the status of abortion bans across the United States, as well as briefs on topics such as medication abortion, insurance coverage, ballot measures, legal developments, and racial and ethnic disparities. It also offers a jumping off point to the latest national and state-specific abortion policies and statistics. Visit the Dashboard →
The Abortion in the U.S. Dashboard is an ongoing research project tracking state abortion policies and litigation following the overturning of Roe v. Wade.
The interactive map shows the increase in states with laws restricting abortion coverage in Medicaid and private insurance in 2010 compared to the present.
This fact sheet provides an overview of the history of the Kemp-Kasten amendment, which states that no U.S. funds may be made available to “any organization or program which, as determined by the president of the United States, supports or participates in the management of a program of coercive abortion or involuntary sterilization,” and examines its current application. Since enacted in 1985, Kemp-Kasten has often been used to withhold funding from the United Nations Population Fund (UNFPA).
Despite for calls from Republican leaders and anti-abortion organizations for the FDA to act quickly, the Louisiana district court has given the FDA until October 7, 2026, one month before the midterms, to file a report with the status of its review and any updated timeframe for completion. In the meantime, clinicians may continue to mail mifepristone to pregnant patients seeking abortions regardless of where they live.
False claims about the safety of mifepristone are driving legislative and investigative action in Congress, even as major medical organizations and decades of clinical evidence support the drug’s safety. And competing interpretations of what censorship and free speech mean are impacting how health misinformation is moderated.
This State and Federal Reproductive Rights Litigation tracker aggregates information about ongoing litigation regarding abortion bans and restrictions, FDA approval of Mifepristone (an abortion pill) and other federal regulations.
This policy tracker documents
exceptions in each state’s most restrictive gestational limit or total ban.
Last updated on March 24, 2026 Since the Supreme Court’s Dobbs decision, overturning Roe v. Wade, voters in 17 states have weighed in on ballot measures regarding abortion-- some more than once. In November 2026, voters in Missouri, Nevada, and Virginia will weigh in on abortion measures that could change the legal status of abortion in their state. In addition, measures in Idaho and Nebraska are in the process of collecting signatures.
This issue brief reviews the abortion-related initiatives currently slated to be on the ballot in November 2026 and examines how these measures may impact abortion access in the state.
Explore an overview of the Mexico City Policy and the Promoting Human Flourishing in Foreign Assistance (PHFFA) Policy
© 2026 KFF
